Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Recurrence 1Leukemia 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Drug Evaluation × Other hematologic neoplasm × Clear all
NCT04500587 2024-09-19

Phase 1 First in Human Study of ZN-d5 as a Single Agent

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute

NCT05758610 2024-05-08

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Myeloid, Acute

NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡